LDRT and Chemoimmunotherapy in NPC With Liver Metastasis
Trial Parameters
Brief Summary
This study aims to evaluate the efficacy and toxicity of adding low-dose radiotherapy to chemoimmunotherapy as a first-line treatment for nasopharyngeal carcinoma patients with liver metastasis.
Eligibility Criteria
Inclusion Criteria: 1. Age ≥ 18 years and ≤ 70 years, male or non-pregnant female. 2. Histologically confirmed with nonkeratinizing carcinoma of the nasopharynx (differentiated or undifferentiated type, WHO II or III) 3. Stage IVB (AJCC 8th edition staging) 4. De novo nasopharyngeal carcinoma with liver metastasis, or patients who had received curative treatment (radical radiotherapy or radical radiotherapy combined with chemotherapy) and developed liver metastasis more than 6 months after treatment completion. 5. ECOG performance status: 0 or 1 6. Must have at least one measurable lesion (assessed according to RECIST v1.1) 7. Absolute neutrophil count (ANC) ≥ 1.5 × 10\^9/L; platelets ≥ 100 × 10\^9/L; hemoglobin ≥ 90 g/L. 8. International normalized ratio (INR) or prothrombin time (PT) ≤ 1.5 × upper limit of normal (ULN); activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN 9. Serum creatinine ≤ 1.5 × ULN or estimated glomerular filtration rate (eGFR) ≥ 60 mL/min. 10. Serum total b